CN103096933A - 多功能抗体缀合物 - Google Patents

多功能抗体缀合物 Download PDF

Info

Publication number
CN103096933A
CN103096933A CN2011800438472A CN201180043847A CN103096933A CN 103096933 A CN103096933 A CN 103096933A CN 2011800438472 A CN2011800438472 A CN 2011800438472A CN 201180043847 A CN201180043847 A CN 201180043847A CN 103096933 A CN103096933 A CN 103096933A
Authority
CN
China
Prior art keywords
mac
antibody
seq
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800438472A
Other languages
English (en)
Chinese (zh)
Inventor
A·S·巴特
C·W·布拉德肖
O·A·劳伦特
R·R·普雷斯顿
D·图梅尔蒂
L·D·伍德
W·H·于
A·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ireland Kaufkes Technology Co ltd
Covx Technologies Ireland Ltd
Original Assignee
Ireland Kaufkes Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ireland Kaufkes Technology Co ltd filed Critical Ireland Kaufkes Technology Co ltd
Publication of CN103096933A publication Critical patent/CN103096933A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2011800438472A 2010-07-12 2011-07-11 多功能抗体缀合物 Pending CN103096933A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36350710P 2010-07-12 2010-07-12
US61/363,507 2010-07-12
PCT/IB2011/053092 WO2012007896A1 (en) 2010-07-12 2011-07-11 Multifunctional antibody conjugates

Publications (1)

Publication Number Publication Date
CN103096933A true CN103096933A (zh) 2013-05-08

Family

ID=44630490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800438472A Pending CN103096933A (zh) 2010-07-12 2011-07-11 多功能抗体缀合物

Country Status (19)

Country Link
US (1) US8741291B2 (enExample)
EP (1) EP2593142B8 (enExample)
JP (2) JP5913307B2 (enExample)
KR (1) KR20130050966A (enExample)
CN (1) CN103096933A (enExample)
AR (1) AR082205A1 (enExample)
AU (1) AU2011277999A1 (enExample)
BR (1) BR112013000951A2 (enExample)
CA (1) CA2804185C (enExample)
CO (1) CO6670522A2 (enExample)
ES (1) ES2704223T3 (enExample)
MX (1) MX2013000491A (enExample)
PE (1) PE20130643A1 (enExample)
PH (1) PH12013500070A1 (enExample)
RU (1) RU2012157167A (enExample)
SG (1) SG186451A1 (enExample)
TW (1) TWI432213B (enExample)
WO (1) WO2012007896A1 (enExample)
ZA (1) ZA201300161B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949575A (zh) * 2015-06-19 2018-04-20 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN108883170A (zh) * 2015-10-23 2018-11-23 索伦托治疗有限公司 可程序化的通用细胞受体及其使用方法
CN118805740A (zh) * 2024-08-07 2024-10-22 中国中医科学院中药研究所 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059873A2 (en) 2010-11-05 2012-05-10 Covx Technologies Ireland, Ltd. Anti-diabetic compounds
MX350954B (es) * 2011-06-21 2017-09-26 Immunogen Inc Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos.
TWI589592B (zh) 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
JP6413127B2 (ja) * 2012-01-09 2018-10-31 コヴェックス・テクノロジーズ・アイルランド・リミテッド 変異抗体およびそのコンジュゲーション
WO2014057687A1 (ja) 2012-10-11 2014-04-17 第一三共株式会社 抗体－薬物コンジュゲート
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
HK1214161A1 (zh) 2012-11-07 2016-07-22 辉瑞公司 抗IL-13受体α2抗体和抗体-药物缀合物
EP2917238A1 (en) 2012-11-08 2015-09-16 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CN105829543B (zh) * 2013-10-14 2021-06-01 西纳福克斯股份有限公司 糖基改造的抗体、抗体-缀合物及其制备方法
CN105814213B (zh) * 2013-10-14 2021-05-04 西纳福克斯股份有限公司 经修饰的糖蛋白、蛋白质-缀合物及其制备方法
PT3088419T (pt) 2013-12-25 2019-01-11 Daiichi Sankyo Co Ltd Conjugado de anticorpo anti-trop2-fármaco
HRP20190431T1 (hr) 2014-01-31 2019-04-19 Daiichi Sankyo Company, Limited Anti-her2 antitijelo-lijek konjugat
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
CN111228511B (zh) 2014-04-10 2024-06-18 第一三共株式会社 抗her3抗体-药物偶联物
US11142571B2 (en) 2014-11-07 2021-10-12 Sesen Bio, Inc. IL-6 antibodies
TWI614264B (zh) * 2015-05-20 2018-02-11 免疫功坊股份有限公司 含胜肽核的多臂接合物及其應用
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
US9623118B2 (en) * 2015-09-01 2017-04-18 Immunwork Inc. Multi-arm linker constructs for treating pathological blood clots
EP3349795B1 (en) * 2015-09-17 2021-03-17 The Scripps Research Institute Dual variable domain immunoconjugates and uses thereof
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
US20220008553A1 (en) * 2015-11-23 2022-01-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
JP2019518017A (ja) 2016-02-09 2019-06-27 アレクサンダー・クランツ トレースレス親和性標識を使用したタンパク質の部位選択的官能化
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
WO2018138591A1 (en) 2017-01-24 2018-08-02 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
TWI855528B (zh) 2017-05-15 2024-09-11 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
KR20250084239A (ko) 2017-08-31 2025-06-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
JP2021502418A (ja) * 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
WO2019140216A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
HRP20240756T1 (hr) 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1-eksatekan antitijelo-lijek konjugat
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
EP3831412A4 (en) 2018-07-31 2022-04-27 Daiichi Sankyo Company, Limited TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP7611825B2 (ja) 2018-08-02 2025-01-10 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
JP7448638B2 (ja) * 2019-08-19 2024-03-12 沈陽薬科大学 抗体の変異体及びその使用
EP4025255A1 (en) 2019-09-04 2022-07-13 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
US12624120B2 (en) 2020-01-31 2026-05-12 Dyne Therapeutics, Inc. Anti-transferrin receptor (TfR) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
CN117980006A (zh) 2021-07-09 2024-05-03 达因疗法公司 用于治疗肌养蛋白病的肌肉靶向复合物和制剂
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
CN118201640A (zh) * 2021-11-01 2024-06-14 达因疗法公司 用于治疗肌养蛋白病的肌肉靶向复合物
EP4508091A1 (en) * 2022-04-15 2025-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
KR20250004770A (ko) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
CN117801107A (zh) 2022-09-30 2024-04-02 上海迪诺医药科技有限公司 苯并氮杂卓衍生物、含其的偶联物及其应用
EP4674840A1 (en) 2023-02-28 2026-01-07 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Chemical coupling linker and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115165A1 (en) * 2002-11-25 2004-06-17 Perry Rosen Bifunctional polyethylene glycol derivatives
US20080166364A1 (en) * 2006-11-10 2008-07-10 Curt Bradshaw Anti-angiogenic compounds
WO2009136352A1 (en) * 2008-05-05 2009-11-12 Covx Technologies Ireland, Ltd. Anti-angiogenic compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
CA2389250C (en) 1999-10-08 2010-07-20 The Scripps Research Institute Antibody catalysis of enantio- and diastereo-selective aldol reactions
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
DK1656391T3 (da) 2003-08-13 2011-01-03 Pfizer Prod Inc Modificerede humane IGF-1R antistoffer
EP1853294A4 (en) 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd ANTIANGIOGENIC COMPOUNDS
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2008295506A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-IGF-1R antibodies and uses thereof
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115165A1 (en) * 2002-11-25 2004-06-17 Perry Rosen Bifunctional polyethylene glycol derivatives
US20080166364A1 (en) * 2006-11-10 2008-07-10 Curt Bradshaw Anti-angiogenic compounds
WO2009136352A1 (en) * 2008-05-05 2009-11-12 Covx Technologies Ireland, Ltd. Anti-angiogenic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LINTAO WANG, ET AL: "Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate,huN901–DM1, by mass spectrometry", 《PROTEIN SCIENCE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949575A (zh) * 2015-06-19 2018-04-20 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN107949575B (zh) * 2015-06-19 2022-03-08 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN108883170A (zh) * 2015-10-23 2018-11-23 索伦托治疗有限公司 可程序化的通用细胞受体及其使用方法
CN118805740A (zh) * 2024-08-07 2024-10-22 中国中医科学院中药研究所 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用

Also Published As

Publication number Publication date
CA2804185C (en) 2017-03-21
JP6339995B2 (ja) 2018-06-06
WO2012007896A1 (en) 2012-01-19
KR20130050966A (ko) 2013-05-16
MX2013000491A (es) 2013-02-26
CO6670522A2 (es) 2013-05-15
EP2593142B8 (en) 2018-12-26
TWI432213B (zh) 2014-04-01
US8741291B2 (en) 2014-06-03
JP2013534535A (ja) 2013-09-05
AR082205A1 (es) 2012-11-21
PE20130643A1 (es) 2013-06-07
SG186451A1 (en) 2013-01-30
ZA201300161B (en) 2013-09-25
CA2804185A1 (en) 2012-01-19
JP2016094455A (ja) 2016-05-26
AU2011277999A1 (en) 2013-01-10
ES2704223T3 (es) 2019-03-15
EP2593142B1 (en) 2018-10-10
JP5913307B2 (ja) 2016-04-27
TW201216986A (en) 2012-05-01
US20120201809A1 (en) 2012-08-09
BR112013000951A2 (pt) 2016-05-17
PH12013500070A1 (en) 2017-08-23
RU2012157167A (ru) 2014-08-20
EP2593142A1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
JP6339995B2 (ja) 多機能性抗体複合体
CN108473591B (zh) 位点特异性her2抗体药物缀合物
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
CN116617410A (zh) 用于癌症治疗的axl特异性抗体药物缀合物
AU2015271100A1 (en) Anti-HER2 antibody-maytansine conjugates and methods of use thereof
TW201617366A (zh) 新穎抗人類Ｔｉｅ２抗體
WO2019068758A1 (en) MODIFIED CYSTEINE MOLECULES BINDING TO ANTIGEN
HK1257352A1 (zh) 靶向gcc的抗体-药物缀合物
TW202221034A (zh) 抗ｃｄ２２８抗體和抗體－藥物共軛體
WO2023178451A1 (en) Anti-folate receptor alpha antibodies and methods of use
TW202442681A (zh) 抗ror1抗體及其藥物偶聯物
WO2021160138A1 (zh) 抗表皮生长因子受体的抗原结合蛋白及其应用
US20250195679A1 (en) Antibody-drug conjugate and use thereof
EP4725968A1 (en) Anti-gpc3 antibody or antigen-binding fragment and use thereof
TW202237135A (zh) 抗體-吡咯并苯并二氮呯衍生物結合物
HK1188384A (en) Multifunctional antibody conjugates
TW202547884A (zh) Ｍｕｃ１６／ｎａｐｉ－２ｂ抗體及使用方法
TW202613168A (zh) 抗cdh17抗體、其抗體藥物偶聯物及其用途
WO2025184730A1 (en) Antibody constructs binding folate receptor alpha and napi2b, conjugates and methods of use
CA3280916A1 (en) Anti-lrrc15 antibody
EA051869B1 (ru) Конъюгат антитело-лекарственное средство и его применение
HK40115552A (zh) 抗ptk7抗体及其用途
HK40099050A (zh) 抗cd228抗体和抗体-药物缀合物
HK1258498B (en) Site specific her2 antibody drug conjugates
HK1258498A1 (en) Site specific her2 antibody drug conjugates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188384

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130508

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1188384

Country of ref document: HK